IFN-lambda Production in CD8+ Dendritic Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The cellular origin of double-stranded nucleic acid-induced interferon-lambda (IFN-λ) production is unclear, and existing methods do not effectively identify or utilize the specific dendritic cell type responsible for its production, which is crucial for anti-infectious and antitumor responses.
Innovation Solution
The method involves generating or obtaining IFN-λ producing CD8+ or eCD8+ conventional dendritic cells by contacting them with Flt3-ligand or M-CSF receptor ligand and double-stranded RNA, and using TLR-ligands or TNF-family members to enhance IFN-λ production, specifically targeting Clec9a and Necl2-positive cells for therapeutic applications in infectious diseases and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to induce IFN-λ production, then IFN-λ is produced by mixed cell populations, but the specific cellular origin and production efficiency remain unclear
Solution Approach 1:
The patent uses flow cytometry with fluorescently labeled antibodies to detect and differentiate dendritic cell subsets based on their surface marker expression patterns. This allows precise identification of CD8α+ cDCs versus CD11b+ cDCs through their distinct immunophenotypic profiles, resolving the cellular origin of IFN-λ production without requiring complex genetic manipulation or functional assays
Solution Approach 2:
The patent employs in vitro differentiation of bone marrow-derived dendritic cells using specific cytokine combinations (GM-CSF and IL-4) to generate defined subsets that mirror in vivo populations. This creates可控 cell models that can be precisely characterized and manipulated to determine which subset produces IFN-λ in response to viral stimulation
2Reliability
If dsRNA is used to induce IFN-λ production, then antiviral response is activated, but the specific dendritic cell subset responsible is not identified
Solution Approach 1:
The patent segments the heterogeneous dendritic cell population into distinct subsets (CD8α+ cDCs and CD11b+ cDCs) based on surface marker expression. By isolating and analyzing each subset separately, the study identifies that CD8α+ cDCs are the specific subset that produces IFN-λ in response to dsRNA stimulation, while CD11b+ cDCs do not, thereby recovering the lost information about cellular origin
Solution Approach 2:
The patent uses Toll-like receptor 3 (TLR3) as an intermediary to mediate the recognition of dsRNA by dendritic cells. By blocking or activating TLR3 specifically, the study demonstrates that TLR3 signaling is required for IFN-λ production in CD8α+ cDCs, providing mechanistic insight into how these cells detect viral RNA and mount an antiviral response
3Productivity
If Flt3-ligand is used to expand dendritic cells, then cell numbers increase, but the proportion of IFN-λ producing cells may be diluted
Solution Approach 1:
The patent applies local quality by providing different cytokine environments for different stages of dendritic cell development. Flt3-ligand is used during the expansion phase to increase overall cell numbers, while GM-CSF and IL-4 are maintained during differentiation to ensure proper subset generation. This staged approach allows both high productivity and preservation of the IFN-λ producing cell population
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively induces IFN-λ production in CD8+ and eCD8+ dendritic cells, enabling their use in preventing and treating viral infections and cancer by enhancing antiviral and immune-modulating functions.
Implementation Method 1
contacting said conventional dendritic cells with a double-stranded (ds) RNA or analog thereof
Implementation Method 2
contacting said population of cells with an agent that increases the level of said conventional dendritic cells, wherein the agent is Flt3-ligand or M-CSF receptor ligand
Implementation Method 3
The population of cells is further incubated with an enhancer of IFN-λ production, wherein the enhancer is a TLR-ligand... and/or a TNF-family member
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
In the present invention, CD8+ conventional dendritic cells (CD8+ cDCs) and equivalents thereof (eCD8+ cDCs) in mouse and human have been established as major source of IFN-lambda (IFN-?) in response to double-stranded (ds) nucleic acids. The invention relates to therapeutic applications of ds nucleic acids or analogs thereof targeting CD8+ and/or eCD8+ cDCs in the prevention and/or treatment of infectious diseases, preferably viral infections, or cancer. Furthermore, the invention relates to an in vitro method for producing IFN-? and/or generating or obtaining a population of IFN-? producing CD8+ or eCD8+ cDCs as well as in vitro method for detecting or screening for CD8+ and/or eCD8+ cDCs. In addition, the invention relates to a Flt3-ligand or a M-CSF receptor ligand for use in increasing the level of CD8+ and/or eCD8+ cDCs in a subject suffering from an infectious disease or cancer.